Bristol-Myers Squibb's Q3 Non-GAAP Earnings Decline, Revenue Increases; 2026 Outlook Updated

07:20 AM EDT, 10/29/2026 (MT Newswires) -- Bristol-Myers Squibb (BMY) reported Q3 non-GAAP earnings Thursday of $1.35 per diluted share, down from $1.63 a year earlier. Analysts polled by FactSet expected $1.10. Revenue for the quarter ended Sept. 30 was $13.07 billion, compared with $12.22 billion a year earlier. Analysts expected $12.72 billion. The company cut its 2026 non-GAAP EPS outlook to between $6.35 and $6.55, from $6.75 to $7.00 previously. Revenue guidance was raised to a range of $49.75 billion to $50.25 billion, compared with the previous outlook of $49 billion to $50 billion. Analysts expect $6.34 in adjusted EPS on revenue of $49.90 billion. Bristol-Myers Squibb shares were up 1.5% premarket.